Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System

Cancer vaccines as promising immuno-therapeutics: platforms and current progress

(2022) Jian Liu et al.   Journal of Hematology & Oncology

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma

(2022) Jonathan Wong et al.   LEUKEMIA

Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells

(2022) Khrystyna North et al.   NATURE BIOTECHNOLOGY

Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma

(2022) Ruichong Ma et al.   NEURO-ONCOLOGY

A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice

(2022) Chih-Jen Wei et al.   Science Translational Medicine

Taming transposable elements in vertebrates: from epigenetic silencing to domestication

(2022) Miguel Vasconcelos Almeida et al.   TRENDS IN GENETICS

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response

(2022) Brandie C. Taylor et al.   Frontiers in Immunology

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

(2022) Virginia Laspidea et al.   JCI Insight

A rare and complete response to combination therapy with radiation and nivolumab in a patient with metastatic urothelial cancer

(2022) Aki Hietala et al.   BMJ Case Reports

A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression

(2022) Daniel Meraviglia-Crivelli et al.   Molecular Therapy-Nucleic Acids

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

(2021) Eryn Blass et al.   Nature Reviews Clinical Oncology

Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control

(2021) Claire Lhuillier et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

(2021) Ying Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas

(2021) Gregory K. Friedman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

(2021) Sydney X. Lu et al.   CELL

Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells

(2021) Vittoria Massafra et al.   JOURNAL OF IMMUNOLOGY

Unboxing the molecular modalities of mutagens in cancer

(2021) Smita Kumari et al.   ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH

Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy

(2021) Limin Tian et al.   GENE THERAPY

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

(2021) Alan J. Korman et al.   NATURE REVIEWS DRUG DISCOVERY

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of antigen-spreading in the efficacy of immunotherapies

(2020) Peter Brossart   CLINICAL CANCER RESEARCH

Endogenous TAP-independent MHC-I antigen presentation: not just the ER lumen

(2020) Margarita Del Val et al.   CURRENT OPINION IN IMMUNOLOGY

Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire

(2020) Sebastian P. Haen et al.   Nature Reviews Clinical Oncology

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

(2020) Kevin Litchfield et al.   Nature Communications

Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors

(2020) Vid Leko et al.   CANCER CELL

Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance

(2019) Jiajie Wei et al.   MOLECULAR CELL

DNMT Inhibitors Increase Methylation in the Cancer Genome

(2019) Anil K. Giri et al.   Frontiers in Pharmacology

Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity

(2019) Guangchuan Wang et al.   NATURE IMMUNOLOGY

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity

(2019) Greta Garrido et al.   Nature Communications

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

(2019) Jenna H. Newman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Intriguing History of Cancer Immunotherapy

(2019) Paula Dobosz et al.   Frontiers in Immunology

Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses

(2019) Anfray et al.   Cells

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Tolerance Induction by Dendritic Cells In Vivo

(2018) Hitoshi Hasegawa et al.   Frontiers in Immunology

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules

(2018) F. Tudor Ilca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability

(2018) A’dem Bokhari et al.   Oncogenesis

Resident memory T cells, critical components in tumor immunology

(2018) Fathia Mami-Chouaib et al.   Journal for ImmunoTherapy of Cancer

Cancer immunoediting and resistance to T cell-based immunotherapy

(2018) Jake S. O’Donnell et al.   Nature Reviews Clinical Oncology

Adoptive cellular therapies: the current landscape

(2018) Maartje W. Rohaan et al.   VIRCHOWS ARCHIV

Specific MHC-I Peptides Are Induced Using PROTACs

(2018) Stephanie M. Jensen et al.   Frontiers in Immunology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

(2017) Samra Turajlic et al.   LANCET ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

(2017) Martin Lauss et al.   Nature Communications

Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice

(2016) Herbert W. Kavunja et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Haidong Wang et al.   LANCET

The rules and impact of nonsense-mediated mRNA decay in human cancers

(2016) Rik G H Lindeboom et al.   NATURE GENETICS

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes

(2016) A. Forero et al.   Cancer Immunology Research

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

(2015) Silvana Konermann et al.   NATURE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

TCR Signaling in T Cell Memory

(2015) Mark A. Daniels et al.   Frontiers in Immunology

5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion

(2014) M. Bhuvanagiri et al.   EMBO Molecular Medicine

Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors

(2014) L. C. Anton et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Insights into the initiation of TCR signaling

(2014) Arup K Chakraborty et al.   NATURE IMMUNOLOGY

Integrative biology of T cell activation

(2014) Bernard Malissen et al.   NATURE IMMUNOLOGY

Reducing INDEL calling errors in whole genome and exome sequencing data

(2014) Han Fang et al.   Genome Medicine

SF3B1 mutations in chronic lymphocytic leukemia

(2013) Y. Wan et al.   BLOOD

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinetics of Antigen Expression and Epitope Presentation during Virus Infection

(2013) Nathan P. Croft et al.   PLoS Pathogens

Estimating the Diversity, Completeness, and Cross-Reactivity of the T Cell Repertoire

(2013) Veronika I. Zarnitsyna et al.   Frontiers in Immunology

Importance of TAP-independent processing pathways

(2012) Claudia C. Oliveira et al.   MOLECULAR IMMUNOLOGY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Repetitive Elements May Comprise Over Two-Thirds of the Human Genome

(2011) A. P. Jason de Koning et al.   PLoS Genetics

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Inflammatory cytokines as a third signal for T cell activation

(2010) Julie M Curtsinger et al.   CURRENT OPINION IN IMMUNOLOGY

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

(2010) Fernando Pastor et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL